{
  "abstract": "Neuroinflammation is a principal driver of brain atrophy and cognitive decline in Alzheimers disease (AD). Here we show that laromestrocel, a mesenchymal stem cell therapy, inhibits progressive brain inflammation in subjects (n=49) with mild AD, with the strongest effect seen in core AD brain regions: the left hippocampus (25 million cells (M)x4 monthly dose group; p<0.001, N=11, and 100Mx4 group; p<0.001; N=10), the left temporal cortex (25Mx4 group; p=0.007; N=11) and left parietal cortex (25Mx4, week 26; p=0.042; N=10), and the medulla (25Mx4 group and 100Mx4; p=0.007; N=11 and N=10) after 39 weeks compared with placebo (N=9). Reduced neuroinflammation correlated with reduced brain atrophy (hippocampus: R=-0.326; p=0.040; N=40) and improvements in clinical scores, particularly cognitive function (hippocampus x MoCA: R=-0.401; p=0.011; N=40). Treated subjects also exhibited reduced neurogranin (25Mx4 group; p=0.023; N=11) in blood plasma, consistent with reduced synaptic loss. Finally, blood biomarker analysis supported a convergent multimodal mechanism of action implicating peripheral immune engagement. Together these results show that long-lasting anti-neuroinflammatory effects of laromestrocel mitigate AD brain inflammation and are associated with markedly reduced brain tissue destruction and improved clinical function.",
  "abstract_shown": true,
  "affiliations": [
    "Longeveron, INC"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "B. G. Rash"
    },
    {
      "name": "S. Levitina"
    },
    {
      "name": "J. Botbyl"
    },
    {
      "name": "C. Conklin"
    },
    {
      "name": "M. Ingalhalikar"
    },
    {
      "name": "J. M. Hare"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8e5yzkfqnt413.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.16.26363132",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1.full",
  "id": "8e5yzkfqnt413",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "neurology"
    ],
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7213553342",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-16",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8e5yzkfqnt413.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:48Z",
      "native_id": "10.64898/2026.09.16.26363132",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:neurology",
      "subfield": "neurology"
    }
  ],
  "title": "Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation",
  "title_text": "Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation",
  "type": "preprint",
  "updated_at": "2026-10-30T12:18:48Z",
  "url": "https://research.draconitic.com/paper/8e5yzkfqnt413",
  "venue": "medRxiv",
  "versions": []
}